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Abstract 70 
Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic 71 
strategies. Although considerable progress has been made in understanding how cancers evade 72 
destructive immunity, measures to counteract tumor escape have not kept pace. There are a 73 
number of factors that contribute to tumor persistence despite having a normal host immune 74 
system. Immune editing is one of the key aspects why tumors evade surveillance causing the 75 
tumors to lie dormant in patients for years through “equilibrium” and “senescence” before re- 76 
emerging. In addition, tumors exploit several immunological processes such as targeting the 77 
regulatory T cell function or their secretions, antigen presentation, modifying the production of 78 
immune suppressive mediators, tolerance and immune deviation. Besides these, tumor 79 
heterogeneity and metastasis also play a critical role in tumor growth.  A number of potential 80 
targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction 81 
of IL-12, use of drugs including phytochemicals have been designed to counter tumor 82 
progression with much success. Some natural agents and phytochemicals merit further study. For 83 
example, use of certain key polysaccharide components from mushrooms and plants have shown 84 
possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, 85 
replicative immortality, deregulated metabolism etc. In this review, we will discuss the advances 86 
made towards understanding the basis of cancer immune evasion and summarize the efficacy of 87 
various therapeutic measures and targets that have been developed or are being investigated to 88 
enhance tumor rejection. 89 
 90 
 91 
Keywords: Cancer, Immune evasion, T cells, Therapy 92 
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1. Introduction 93 
Cancer remains one of the leading causes of death globally, with an estimated 12.7 million cases 94 
around the world affecting both sexes equally. This number is expected to increase to 21 million 95 
by 2030. The immune system interacts intimately with tumors over the entire process of disease 96 
development and progression to metastasis. This complex cross talk between immunity and 97 
cancer cells can both inhibit and enhance tumor growth and is now classified as a hallmark of 98 
cancer [1].  The balance of these actions between and across the hallmarks determines the 99 
eventual outcome, which in the case of clinically overt cancer results from evasion of the 100 
destructive elements of the immune response by the tumor. Mechanisms resulting in evasion of 101 
immune attack include the selection of tumor variants resistant to immune effectors (sometimes 102 
designated “immunoediting”) and progressive formation of an immune suppressive environment 103 
within the tumor. Although considerable knowledge has been accumulated on how tumors avoid 104 
immune destruction, discovering effective cancer therapies still remains a daunting task for the 105 
researcher and clinician. In this report, we will briefly present an overview of how tumors evade 106 
immune surveillance by focusing on how the immune system reacts to the development of 107 
tumors, how certain cancers evade immunity, and what measures can be taken to eradicate 108 
cancer. We will address important aspects of tumor and host immune interactions as set out 109 
below. 110 
 111 
2. Tumors and immunity  112 
The involvement of the host immune system in cancer progression is well established, although 113 
greater emphasis has been placed on tumor eradication by immunity than tumor immune 114 
potentiation, which may be equally important. These interactions between the immune system 115 
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and the tumor occur through complex events that usually eventually climax either in successful 116 
tumor eradication or immune evasion by the tumor [2].  117 
2.1 Relationship between tumor formation and immune responses 118 
Tumor development and survival is a chaotically governed process involving the interplay 119 
between cancer cells, normal stromal cells and host defense mechanisms. Several other factors 120 
such as cellular changes due to infection or disease-induced stress may also contribute to tumor 121 
growth or tumor suppression. Generally, CD8+ cytotoxic T cells (CTL) and CD4+ helper T (Th)1 122 
cells curb cancer development via mechanisms commonly involving their production of 123 
interferon (IFN)-γ and cytotoxins [3] but other factors such as chronic inflammation may 124 
override these effects to promote cancer development [4,5]. For example, the risk of overt 125 
hepatocellular carcinoma (HCC) appears to be closely linked to the duration of the Hepatitis B 126 
and C viral-induced inflammatory state [6-9]. Compelling evidence has also documented, both in 127 
animal tumor models and in human cancers, that chronic inflammation plays a critical role in the 128 
development of colon and pancreatic cancers [6]. Therefore, when beneficial acute responses fail 129 
to resolve tumors/cancer, lingering chronic inflammation can lead to promotion of tumor cell 130 
growth and angiogenesis [6,10]. In addition, ongoing activity due to autoimmune disease has 131 
also been shown to support development of many cancers including lymphoma [6,10-12]. 132 
2.2 Tumor progression and immunity  133 
Vital fundamental discoveries made over the last few decades have unequivocally shown that the 134 
immune system plays a critical role in maintaining an equilibrium between immune recognition 135 
and tumor development with a dual capacity to both promote and suppress tumor growth. These 136 
discoveries collectively support the concept of “immunoediting” and help to explain why tumors 137 
can sometimes lie dormant in patients for years before re-emerging, and why tumors grow 138 
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despite the host having a fully functional immune system [13]. During cancer immune editing, 139 
the immune system is able to recognize and destroy the most immunologically vulnerable cancer 140 
cells because they present tumor antigens, resulting in their elimination [14]. Nonetheless, due to 141 
genetic instability, constant tumor cell division can generate with reduced immunogenicity that 142 
can evade immune elimination. This state of production of new tumor cell variants balanced by 143 
the elimination has been dubbed “equilibrium”, during which the cancer cells continue to divide, 144 
accumulating mutational changes by chance or in response to immune-induced inflammation. 145 
Thus, a balance between immune control and tumor growth is maintained, giving the appearance 146 
of tumor dormancy [15]. However, these processes eventually enable tumors to impair the 147 
capacity of the immune system to eradicate them by immune suppressive effects or by loss of 148 
target antigen expression. It is at this stage that tumor escape occurs, resulting in overt clinical 149 
cancer. Nonetheless, there may also be conditions under which tumor cells are truly dormant, for 150 
example by induction of “senescence”. In this case, they would be likely to remain dormant 151 
permanently, as replicative senescence is generally believed to be irreversible [16].  152 
2.3 Factors that tumors exploit to avoid immune responses 153 
2.3.1. Regulatory cells  154 
Immune suppression in the tumor microenvironment, mediated by CD4+CD25+ FoxP3+ 155 
regulatory T cells (Tregs), or other types of suppressive cells, seems to be a major mechanism of 156 
tumor immune escape and can be a crucial hurdle for tumor immunotherapy [17]. A number of 157 
studies have shown that tumor-derived Tregs have comparatively higher suppressive activity 158 
than naturally occurring Tregs [18,19]. Tregs are drawn into the tumor microenvironment via 159 
tumor cell-mediated chemokine production [20,21]. Evidence also suggests that transforming 160 
growth factor (TGF)-β, produced by tumor cells among other cells, aids conversion of CD4+ T 161 
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cells into suppressive Tregs in situ [22]. Thus, elimination of Tregs by anti-CD25 monoclonal 162 
antibodies (mAbs) or by other means may promote tumor rejection. Myeloid cells, especially 163 
“myeloid-derived suppressor cells” (MDSCs), modulated dendritic cells (DCs) and alternatively-164 
activated M1 and M2 macrophages create an inflammatory microenvironment and can also act as 165 
mediators of tumor initiation, angiogenesis, and metastasis [23,24]. Moreover, a vicious cycle 166 
may be instigated in that higher levels of inflammatory mediators confer resistance to apoptosis 167 
in MDSCs which would otherwise be subject to downregulation by T cells in complex 168 
interaction networks [25]. Thus, CD11b+Gr1+ MDSCs suppress CD8+ T cell-mediated antitumor 169 
immunity [26], one mechanism for which may be TCR ζ-chain downregulation. MDSCs with 170 
this phenotype accumulate in, for example, melanoma lesions in a manner intimately linked to 171 
the inflammatory milieu, implying that the tumor inflammatory microenvironment supports 172 
MDSC recruitment and immunosuppressive activity. Reduction of chronic inflammatory 173 
mediators by pharmacological means can reduce the amounts of MDSC and decrease 174 
immunosuppression [27]. CD11b+F4/80+ macrophages having an M2 phenotype produce high 175 
levels of TGF-β, IL-10, and vascular endothelial growth factor (VEGF) and promote tumor 176 
growth [28-30]. In addition, a number of tumor-derived factors and gangliosides have been 177 
reported to alter DC phenotype. These immature, functionally-impaired DCs have lower levels of 178 
CD80, CD86, CD40, and high indoleamine 2,3-dioxygenase (IDO) expression that also 179 
contributes to suppression of T cell immunity [31].  180 
2.3.2. Defective antigen presentation  181 
It is well established that another fundamental mechanism by which tumors evade immune 182 
surveillance is by down-modulating antigen processing machinery affecting the major 183 
histocompatibility complex (MHC) I pathway, proteosome subunits latent membrane protein 184 
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(LMP)2 and LMP7, transporter associated with antigen processing (TAP) protein, and tapasin 185 
[32-37]. Thus, expression of tumor antigen is downregulated, which can lead to enhanced tumor 186 
incidence and metastasis because cytotoxic T lymphocyte (CTL) can no longer recognize target 187 
antigens on the tumor cells [38].  188 
2.3.3. Immune suppressive mediators  189 
As alluded to above, tumors can evade immune surveillance by crippling CTL functionality via 190 
production of several immune suppressive cytokines, either by the cancer cells or by the non-191 
cancerous cells present in the tumor microenvironment, especially including immune cells and 192 
epithelial cells. TGF-β is a chief mediator of this activity [39]. In addition, tumor necrosis factor 193 
(TNF)-α, IL-1, IL-6, colony stimulating factor (CSF)-1, IL-8, IL-10, and type I IFNs can also 194 
significantly contribute to cancer growth [40-44]. In addition to immune suppressive cytokines, 195 
other factors such as VEGF produced by tumors, inhibit the differentiation of progenitors into 196 
DCs [45], thus affecting efficient uptake and antigen presentation. VEGF and IL-10 and TGF-β 197 
are also known inhibit maturation of DCs. DCs retaining the immature phenotype are tolerogenic 198 
as they do not present antigen in the proper context (with appropriate costimulation to T cells 199 
[46]. Other factors such as tumor gangliosides and receptor-binding cancer-associated surface 200 
antigen (RCAS1) also contribute to tumor progression [47,48]. Additional studies revealed that 201 
expression of RCAS1is associated with apotosis of tumor infiltrating lymphocytes (TILs) [49-202 
50]. Similarly, ganglioside antigens, on cell surface or shed from cells surface, are known to 203 
suppress CTL and DC function [51]. Immunosuppressive enzymes such as IDO, arginase, and 204 
inhibitor of nuclear factor kappa-B kinase (IKK)2 may also contribute significantly to tumor 205 
progression [52-55] via direct actions on tumor cell proliferation or through induction of T cell 206 
tolerance/suppression [56-58]. 207 
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2.3.4. Tolerance and immune deviation  208 
Most tumor cells fail to express costimulatory molecules and can thereby induce anergy or 209 
tolerance in T cells by engaging the T cell receptor in the absence of costimulation [59]. Tumors 210 
are also known to evade immune attack by shifting the balance from Th1 to Th2 (immune 211 
deviation) in a TGF-β- and IL-10-dependent manner [60]. In addition, tumor expression of 212 
inhibitory molecules like programmed cell death (PD)-L1/B7-H1 has been shown to cause 213 
deletion or anergy on tumor reactive cells [61,62]. There is also evidence that down regulation of 214 
death receptors prevents death ligand-mediated killing of tumor cells by both CTLs and natural 215 
killer (NK) cells [63]. Slavin-Chiorini et al [64] have demonstrated that CTL studies in 216 
conjunction with antibody blocking studies enhanced antitumor effector activity mainly through 217 
CD54. There are reports to show that p53 tumor suppressive gene is implicated in the regulation 218 
of tumor cell death by CTLs [65].  Thus, factors promoting tolerance and immune deviation are 219 
significant contributors to cancer immune evasion. 220 
2.3.5. Apoptosis 221 
A number of studies have shown that cancer cells delete tumor-specific CTLs through apoptosis 222 
[66,67]. The different influences governing tumor growth and immune evasion strategies are 223 
briefly outlined in Figure 1. 224 
 225 
3. Tumor heterogeneity and immune responses  226 
Cells of the immune system can inhibit tumor growth and progression through the recognition 227 
and rejection of malignant cells containing initiation mutations. Though tumors originate from a 228 
single transformed cell, due to genetic instability, they commonly become genetically 229 
heterogeneous, exhibiting multiple phenotypes both in terms of morphology and physiology. 230 
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They also display striking heterogeneity in cell surface molecule expression, proliferative and 231 
angiogenic potential [68], which is believed to stem from morphological and epigenetic 232 
plasticity. Thus, the tumor cells express a wide variety of antigens including some which may be 233 
tumor-specific or tumor-associated, differentiation antigens, and lectin-binding sites. These 234 
antigens are unevenly distributed on tumor subpopulations and induce different immune 235 
responses to the same determinant [69]. This tumor antigenic heterogeneity has a significant 236 
effect on genotype, gene expression, cellular morphology, metabolic activity, motility, and 237 
behavior such as proliferation rate, antigen expression, drug response and metabolic potential 238 
[70-74]. Such heterogeneity has important implications for diagnosis, treatment efficacy, and the 239 
identification of potential targets [70,75]. The key aspects of tumor heterogeneity and its 240 
subsequent effects on tumor growth are briefly outlined in Figure 2. 241 
 242 
4. Immune system and cancer metastasis  243 
It is fascinating how cancer cells migrate throughout the body from their original location to 244 
establish themselves at a new location [76]. How this exodus of tumor cells occurs is only now 245 
beginning to be understood. In general, cancer cells detach from the primary tumor and travel 246 
through the surrounding tissues and basement membranes, avoid immune destruction and 247 
metastasize to distant organs [77,78]. This metastatic process is what is responsible for most 248 
cancer deaths [79-82]. Although there are several underlying mechanisms of tumor 249 
dissemination and colonization [83], the “progression model” which suggests that a series of 250 
mutational events occur either in a subpopulation of primary tumor or in disseminated cells, 251 
resulting in a small fraction of the cells that acquire full metastatic potential is a well-accepted 252 
theory [84]. This view has been corroborated by a number of investigations [85-88]. Among 253 
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other factors, once again, it is the TGF-β secreted by the cancer cells that makes a major 254 
contribution to tumor metastasis [89]. In addition, the vasculature also plays an important role in 255 
metastatic seeding at different sites. It has been shown that tumor vasculature hyperstimulated by 256 
VEGF often has reduced pericyte coverage and that looser association of such pericytes with the 257 
endothelium facilitates metastatic dissemination [90]. In addition, hypoxia in and around tumor 258 
vessels also contributes to metastatic dissemination of cancer cells in an hypoxia inducible factor 259 
(HIF)-, VEGF-, and inducible nitric oxide synthase (iNOS)-dependent manner [91,92]. Notably, 260 
hypoxia promotes the formation of pre-metastatic niches through the production of lysyl oxidase 261 
[93]. Hypoxia further conditions pre-metastatic niches by recruiting MDSCs and suppressing NK 262 
cell functions [94]. In support of a role for immunosurveillance in controlling tumor metastasis, a 263 
recent study revealed that high expression of Irf7-regulated genes in primary human breast 264 
tumors is associated with prolonged bone metastasis-free survival [95]. A brief overview of the 265 
events promoting tumor metastasis and the involvement of immune responses is provided in 266 
Figure 3. 267 
 268 
5. Conventional cancer therapy and the immune system 269 
Although a variety of agents have been screened for their antitumor effects and some have been 270 
approved for the treatment of cancer patients, chemotherapy, radiation therapy, and surgery 271 
remain the mainstays of standard cancer therapeutic strategies. A downside to these therapies is 272 
their ability to cause a transient immune suppression which in turn increases the risk of infection 273 
and is also likely to decrease the immune system’s ability to inhibit further development of 274 
cancer. For example, standard chemotherapy decreases the host’s native immune competent cells 275 
including T cell populations. However, this transient loss of immune activity has been shown to 276 
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return 2-3 weeks after chemotherapy [96]. In addition, patients are at risk for viral, fungal, and 277 
parasitic infections, and when chemotherapy continues long-term, these patients may 278 
permanently lose their cell-mediated immune function [97]. Nevertheless, recent evidence 279 
suggests that some chemotherapeutic drugs rely on the induction of anticancer immune responses 280 
for therapeutic activity by inducing a type of tumor cell death that is “immunogenic” [98]. The 281 
immune-stimulating property of some chemotherapeutic drugs, such as anthracyclines and 282 
oxaliplatin, requires preapoptotic translocation of calreticulin (CRT) on the tumor cell surface, 283 
post-apoptotic release of the chromatin-binding protein high mobility group B1 (HMGB1), and 284 
extracellular release of ATP. Interestingly, phosphohydrolysis of extracellular ATP by ecto-285 
nucleotidases (i.e. CD39 and CD73) acts as a counterbalancing process to chemotherapy-induced 286 
immunogenic cell death [99].Other chemotherapies appear to alter the phenotype of surviving 287 
tumor cells making them better targets for immune cells [100,101].  Radiation therapy has also 288 
been shown to impact cell-mediated immunity. On the one hand, radiotherapy can suppress 289 
antitumor immunity, presumably due to the high radiosensitivity of lymphocytes [102]. There are 290 
also reports to suggest that high doses of total lymphocyte irradiation increase T suppressor cell 291 
activity and loss of the ability to recognize autoantigens [103]. On the other hand, low doses of 292 
radiation result in the generation of reactive oxygen species (ROS) leading to the activation of 293 
intracellular signaling pathways that induce T cell proliferation and differentiation [104,105]. 294 
Radiation has been shown to alter the phenotype of cells resulting in increased expression of 295 
death receptors [106], chemokines [107], adhesion molecules such as intercellular adhesion 296 
molecule (ICAM)-1 and MHC-I [108], and costimulatory molecules [109, 110] on tumor cells. 297 
Moreover, tumor cells surviving radiation have also been shown to be more sensitive to cytolysis 298 
by T cells [108, 111].  Radiation has also been shown to result in the increased expression of 299 
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proinflammatory cytokines such as TNF-α and IL-1β that activate antigen presenting cells 300 
(APCs) [112,113]. Radiotherapy can thus trigger significant antitumor immune responses, 301 
related to the well-known abscopal effect, that is, the regression of metastases upon irradiation of 302 
the primary tumor, despite the metastasis being outside of the radiation field [114,115]. It is 303 
indeed generally accepted that radiotherapy depends to some degree on the activation of 304 
antitumor immune responses for its efficacy [116]. 305 
Finally, trauma due to surgical resection of tumors has profound effects on the immune system 306 
because of increased production of proinflammatory cytokines and other immune modulators 307 
like IL-6, C-reactive protein (CRP), TNF-α, IL-1β etc [117,118]. Also, decreased delayed-type 308 
hypersensitivity (DTH) reactions, due to surgery, pose a risk for infection [119]. To overcome 309 
surgery-mediated transient immune suppression, the introduction of laparoscopic methods may 310 
reduce such suppression and thus decrease tumor growth [120]. Conversely, surgery has also 311 
been shown to induce danger/damage that enhances antitumor efficacy and reduces metastasis 312 
[121]. There is evidence that tumor growth control can actually potentiate rather than curb 313 
metastasis, again illustrating the general finding that very similar pathways can have either 314 
inhibitory or facilitatory activity on tumor growth. A case in point is that chemotherapy, 315 
radiotherapy, and biological/targeted therapies can promote tumor metastasis via the so-called 316 
tumor bed effect [122,123]. Currently, both primary and metastatic cancers are treated by similar 317 
approaches where radiation is often the mainstay choice of therapy [124]. Surgery is rarely 318 
performed on metastatic lesions. Thus, these standard anticancer therapies, although they can be 319 
effective alone, will have enhanced therapeutic efficacy when combined with agents that boost 320 
the weakened immune system, if we are able to learn how to avoid potential tumor growth 321 
stimulatory effects. 322 
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6. Strategies for cancer immunotherapy  323 
Tumor cells have developed multiple mechanisms for evading immune surveillance. Current 324 
treatments for cancer include chemotherapy, radiation therapy, immunotherapy, targeted therapy, 325 
and surgery which all have limitations and detrimental side effects [125]. Recent investigations 326 
have identified several classes of anticancer agents that are targeted, efficient, and have less 327 
adverse side effects. An increasing number of clinical trials are currently underway to stimulate 328 
the immune system to combat cancer. Important among these include vaccination with peptides 329 
[126], vaccination with DCs [127], vaccination with viral-based vectors [128,129] and 330 
immunotherapy with autoreactive effector cells [130].  Interestingly, there are also studies to 331 
show that administration of bacteria can increase tumor immunogenicity [131]. For example, 332 
treatment with Clostridium novyi-NT is shown to attract many inflammatory cells such as 333 
neutrophils, monocytes, and lymphocytes that can kill tumor cells [132]. Especially important 334 
will be the extended use of immunomodulatory antibodies which have recently yielded such 335 
dramatic effects in highly refractory tumors (see below). Many clinical trials of all these 336 
approaches, and especially combinations thereof, are currently ongoing and hold great promise. 337 
6.1. Cellular targets  338 
In addition to the obvious targets, the tumor cells themselves, some of the several regulatory 339 
cells including regulatory B cells or their products implicated in tumor escape are currently being 340 
targeted to promote tumor rejection. For example, IDO is an immunoregulatory enzyme which 341 
suppresses T-cell immunity but can be targeted in the tumor microenvironment by IDO-reactive 342 
CD8+ T cells. It was shown that IDO-specific T cells could enhance tumor immunity by 343 
eliminating IDO+ suppressive cells and changing the regulatory microenvironment [133]. 344 
As mentioned above, important among suppressive cells are Tregs, which are powerful inhibitors 345 
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of antitumor immunity and an impediment to successful immunotherapy [22]. In support of this, 346 
inhibition of Tregs by monoclonal antibodies has been shown to decrease tumor development 347 
[134,135]. In addition, other regulatory cell populations such as MDSCs which accumulate in 348 
spleen, blood, tumors, and bone marrow of tumor-bearing mice and cancer patients [136,137] 349 
have been considered as important targets for therapeutic intervention [138]. MDSCs secrete IL-350 
10 and TGF-β and enhance angiogenesis and metastasis by inducing Treg production [23,139]. 351 
Increasing evidence suggests that the M2 macrophages promote tumor growth and metastasis, 352 
and strategies to target these cells are also being developed [140]. Type II NK cells are also 353 
known to contribute to tumor development via their secretion of characteristic cytokines. About 354 
60% of murine NK cells express Ly49 and CD94/NKGA inhibitory receptors, the blockade of 355 
which augments antitumor activity [3,141,142]. In addition, regulatory DCs (expressing CD25, 356 
PD-1, PD-L1, IL-10, TGF-β, kynurenine, IDO, cyclooxygenase (Cox)-2, and arginase (Arg)-1) 357 
play a significant role in tumor development [143] and therapies directed against these cells have 358 
also been investigated [144]. 359 
6.2. Molecular targets  360 
In addition to cellular targets, several molecular targets including cytotoxic T-lymphocyte-361 
associated protein 4 (CTLA)-4 [145], 4-1BB [146], PD1/PD-L1 [147], and activation-inducible 362 
TNFR (AITR), T cell immunoglobulin mucin (TIM)-3, Lymphocyte-activation gene (LAG)-3, 363 
OX40, CD40, CD39, CD73, A2A [148] and cancer antigens of different types, such as 364 
melanoma-associated antigen (MAGE) family members and NY-ESO-1, human telomerase 365 
reverse transcriptase (hTERT) and Wilm’s tumor (WT)1 have been considered as important 366 
antitumor targets [149]. In melanoma, MAGE, B melanoma antigen (BAGE), and G antigen 367 
(GAGE) family antigens have been targeted for therapeutic vaccination [150,151]. The L antigen 368 
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family member (LAGE)-1 gene closely related to NY-ESO-1 may also be an appropriate target 369 
[152]. The preferentially expressed antigen in melanoma (PRAME) is also a melanoma-370 
associated antigen recognized by CTL [153]. Human telomerase activity and hTERT expression 371 
are detected in a majority (>90%) of human cancer cells [154]. To increase potential efficacy, 372 
hTERT promoters have been utilized for cancer gene therapy [155,156]. Wilms’ tumor gene 373 
WT1 is expressed in several different cancers and illustrates the general principle that tumor 374 
escape from immunity as a result of downregulation of target antigen expression is unlikely to 375 
occur when the gene product has an essential role in tumorigenesis [157]. A number of studies 376 
suggest that the WT1 protein is a promising target for cancer immunotherapy [158,159].  377 
Targeting cell surface molecules other than tumor antigen targets for antibody-based therapeutic 378 
intervention of cancer is becoming an important available option for the clinician. Of these, so 379 
far only anti-CTLA-4 (ipilimumab) has been approved for clinical use in the USA, Canada, 380 
United Kingdom, and European Union [160,161], but PD1 and PD-L1-specific antibodies will 381 
surely be licensed very soon. Ipilimumab is currently in phase III clinical trials for the treatment 382 
of prostate cancer [162] and for cancers of the lung [163] and kidney [164] as well as melanoma. 383 
In one recent trial, administration of the anti-PD-1 antibody nivolumab showed unprecedented 384 
therapeutic objective responses in 18-28% of patients with advanced non-small-cell lung 385 
carcinoma, melanoma, and renal cell carcinoma [165]. While CTLA-4 and PD-1/PD-L1 blocking 386 
Abs have shown efficacy by blocking inhibitory signals to responding T cells, agonist Ab to 387 
OX40 and 4-1BB propel T-cell immunity by sending stimulatory signals. Several clinical trials 388 
are underway investigating their therapeutic properties [166]. Targeting Tregs by anti-CD25 389 
antibodies showed inhibition of neuroblastoma tumors in mice [167]. There are also data 390 
demonstrating that activation of the signal transducer and activator of transcription (STAT)3 391 
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signaling pathway supports tumor development by inducing accumulations of MDSCs and 392 
inhibition of DC differentiation [168]; hence its inactivation leads to inhibition of cancer 393 
development by a DC- and Treg-dependent mechanism [169].  394 
Targeting immunosuppression by soluble mediators is another attractive approach for cancer 395 
immunotherapy. A plethora of immunosuppressive factors has been associated with 396 
tumorigenesis, including TGF-β, IDO, arginase, prostaglandin-E2 (PGE2) and extracellular 397 
adenosine. Recent studies have shown that extracellular adenosine, essentially produced by the 398 
ecto-nucleotidase CD73, plays an important role in tumor development and metastasis [170-399 
175]. These findings are corroborated by studies using mice deficient in CD73 or the high 400 
affinity A2A adenosine receptor [174-177]. These animals exhibit increased CTL-mediated 401 
antitumor immunity [178]. Inhibition of pH regulatory molecules and certain heat shock proteins 402 
limit cancer cell-mediated immune suppression. Targeting these molecules could simultaneously 403 
counteract the metastatic potential of cancer cells and restore antitumor immune surveillance. 404 
The above-mentioned cancer therapeutic targets and their beneficial effects are briefly outlined 405 
in Figure 4. 406 
6.3. Vaccination therapy (Peptide, DNA, and DC)  407 
Several studies demonstrated the efficacy of therapeutic viral vaccines [179]. Peptide vaccines 408 
derived from tumor-associated antigens (TAA) may significantly contribute to immune 409 
enhancement or tumor regression. Many TAAs have been identified and molecularly 410 
characterized. However, so far only a limited number of TAA peptides, mostly recognized by 411 
CD8+ T cells in melanoma patients, have been clinically tested. In some clinical trials, partial or 412 
complete tumor regression was observed in 10-30% of patients [180]. Peptides such as melan-413 
A/MART-127-35 and gp100, which readily activate specific T cells in vitro [181] and in vivo 414 
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[182,183], show limited immunogenicity when used as vaccines for cancer patients [184,185]. 415 
Alternatively, DNA cancer vaccines may also represent an effective approach [186]. Such 416 
vaccines, although having many variants, utilize the same basic principle involving the isolation 417 
of DNA from cancer cells and subsequent transfer, most commonly via the intramuscular route, 418 
into tumor-bearing individuals. It has been shown that the administration of DNA vaccines via 419 
the intramuscular route effectively primes both the adaptive as well as innate arms of the 420 
immune system [187]. While naked DNA is quite sturdy and stable at different temperatures, and 421 
retains immune activating abilities, plasmid DNA vaccines are less immunogenic [188]. 422 
Refinements to the existing DNA vaccination strategies are showing promising results. Among 423 
these, the use of an electrical pulse, commonly called electropermeabilization, electroporation or 424 
electrotransfer [189] is currently used in preclinical protocols and has been shown to have strong 425 
immune activating abilities [190]. Recent therapeutic studies involving DNA vaccines have 426 
shown promise, for example, for the treatment of glioma. Incorporation of cancer cell DNA into 427 
healthy immune competent cells and subsequent transfer into tumor-bearing mice showed 428 
decreased tumor burden and increased survival of both spontaneous as well as established 429 
tumors. Further analysis revealed that DNA vaccine-mediated antitumor activity in the above 430 
case involved over-production of IFN-γ and participation of T and NK/lymphokine activated 431 
killer (LAK) cells [191,192]. Adoptive transfer of peptide-pulsed DC [193] is also an option. In 432 
all cases, it takes a long time to develop such therapies and the newest results now being 433 
published suggest that peptide vaccinations with selected multi-peptide vaccines, combined with 434 
immunomodulatory agents, may indeed achieve impressive results. Thus, a phase II multi-center 435 
granulocyte macrophage colony stimulating factor (GM-CSF)-adjuvanted multipeptide vaccine 436 
for refractory late-stage renal cancer patients has yielded unprecedented 3-year survival benefits 437 
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especially in those patients able to respond to more than one peptide, provided they had received 438 
a pulse of low-dose cyclophosphamide prior to vaccination. It was proposed that the 439 
cyclophosphamide reduced the Tregs in the patients, for which some evidence was presented 440 
[194,195]. The United States FDA has approved the use of sipuleucel-T, a cellular product made 441 
of blood APCs cultured with a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF 442 
[196]. Efficacy studies revealed a 4-month extended median survival in patients with prostate 443 
cancer [197]. 444 
6.4. Cross Validation 445 
A cross-validation team conducted a peer-reviewed literature review of the targets and 446 
approaches listed in Tables 1 and 2, and these evidences of cross- hallmark activity are 447 
referenced accordingly. This process led to the creation of two unique matrices, whereby a series 448 
of candidate compounds and molecular/cellular targets were identified for having immune 449 
system evasion mechanistic relevance. The complete mapping of these candidate targets and 450 
actions was screened for known complementary, contrary or combinations of actions across all 451 
cancer hallmarks described in Hanahan and Weinberg [1].  For example, inhibiting or 452 
stimulating an immune evasion target may or may not have been examined in other hallmark 453 
mechanism.  Each potential target-hallmark or approach-hallmark interaction was considered to 454 
have either a pro- or anti-chemotherapeutic effect. There were also mixed indications or many 455 
instances where no known relationship existed. In summary, the findings gathered in this effort 456 
varied considerably by each hallmark. These tables provide information that can serve as a 457 
starting point for future basic and translational research on phytochemical combinations for 458 
immune evasion targets and for chemotherapeutic applications.  459 
 460 
6.5. Phytochemicals 461 
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Besides these conventional immunotherapeutic approaches, several phytochemicals have been 462 
shown to facilitate tumor regression. Prominent among these are isothiocyanate, curcumin, 463 
genistein, epigallocatechin gallate, lycopene, resveratrol, and glucosinolates. Some have entered 464 
clinical trials and are beginning to yield encouraging results [198]. There are other natural, plant-465 
derived or nutrient substances, including flavonoids, omega-3 fatty acids, zinc, and vitamin C, 466 
that are purported to strengthen the immune system [199-202], yet their roles as nutrients to 467 
resolve inflammation or assist in suppressing tumorigenesis are not clear from human studies. 468 
Too often, these alternative or complementary agents are not evaluated with standard sets of 469 
clinical outcomes that are needed to advance our understanding of how nutritional components 470 
and phytochemicals may enhance tumoricidal immunity or inhibit tumor immune evasion 471 
mechanisms described above. While some dietary supplements have been shown to enhance the 472 
ability of NK cells to identify and destroy dysfunctional cells, such as infected or cancerous cells 473 
[203,204], these studies have not comprehensively assessed increased T cell production of 474 
cytokines such as IFN and TNF, or reduced secretion of immune suppressive factors from 475 
tumors. The emerging evidence for dietary supplement doses that far exceed physiological 476 
nutrient exposures suggests that some bioactive food components can even be hazardous [205], 477 
and are now largely discouraged for consumption during cancer treatment [206]. Table 2 478 
summarizes potential targets and approaches that may enhance anticancer immune responses. 479 
 480 
[Tables 1 and 2 about here] 481 
 482 
6.6. Adoptive T cell therapy 483 
Autoreactive T cells are potentially tolerant to self-tissues, due to diverse mechanisms in the 484 
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periphery [295]. Adoptive T cell therapy involves the isolation and expansion of autologous T 485 
cells specific for tumor antigen and their subsequent re-infusion into the patient. Tumor-reactive 486 
T cells such as tumor-infiltrating lymphocytes (TIL) combined with IL-2 showed potentially 487 
interesting results already in the 1980´s, but objective response rate was low in metastatic 488 
melanoma patients [296,297]. In 2002, Rosenberg and colleagues [298,299] introduced a 489 
lymphodepletion regimen before administering adoptive T cell therapy, resulting in elimination 490 
of the immune-suppressive cells, increase of key cytokines for T cells such as IL-7 and IL-15, 491 
and creation of a space for T-cell proliferation. When lymphopenia is induced, remaining 492 
peripheral T cells initiate homeostatic proliferation to reconstitute the lost T cells, and the 493 
tolerant autoreactive CD8+ T cells acquire an opportunity to proliferate and become functional 494 
[300,301]. This may be one mechanism by which self-tumor Ag-specific T cells are increased in 495 
cancer patients after chemo- or radio-therapy [302,303].  This lymphodepletion treatment 496 
markedly improved the clinical efficacy of adoptive cell therapy using TILs, with an objective 497 
response in ~70% of melanoma patients and complete durable regressions were found in ~50% 498 
[304]. Rosenberg et al [305] have demonstrated objective cancer regression in patients with 499 
metstatic melanoma. Though good clinical outcome has been observed by Rosenberg et al [305], 500 
generating T cells for adoptive T cell therapy is a cumbersome process.  There have been many 501 
efforts to develop a practical protocol to produce autologous self-tumor Ag-specific T cells, but 502 
most of them are still complicated and time-consuming because self-tumor Ag-reactive T cells 503 
exist as a minor population. Recently, however, an efficient method has been developed to 504 
produce tumor-specific CD8+ T cells from ~50 mls of peripheral blood mononuclear cells based 505 
upon the unique property of 4-1BB (CD137) to be selectively expressed on antigen-engaged T 506 
cells [306]. Clinical trials with various solid tumors are underway to test the safety and efficacy 507 
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of the CTLs thus generated. To overcome major hurdles in the preparation of autologous self-508 
tumor Ag-specific T cells, gene-modified T cells like TCR or chimeric Ag receptor (CAR)-509 
modified T cells were developed [307]. Currently, these gene-modified T cells are being tested 510 
for safety and efficacy in the clinic and clinical results will tell us whether adoptive T cell 511 
therapy could provide a new opportunity for cancer patients who failed to respond to standard 512 
therapies. However, the many mechanisms of tumor escape discussed above (tumor suppression, 513 
downregulation of target antigens etc.) need to be considered and counteracted in combination 514 
with these modalities.   515 
 516 
7. Conclusions 517 
Here we wish to emphasize that immunotherapeutic approaches may advance via the inclusion of 518 
holistic or integrative therapy of cancer. Especially, we want to emphasize that dual approaches 519 
which seek to 1) eliminate immune suppressing factors, and 2) enhance tumor-killing activities 520 
will be necessary to achieve successful cancer therapy. In view of the immune suppressive 521 
factors present in the tumor microenvironment from the very earliest stages of tumor formation, 522 
nontoxic agents that control or eliminate the immunosuppressive factors can be used for therapy 523 
of cancer or also utilized as cancer control and chemopreventive agents. A tumor-killing agent 524 
requires us to aim at cross-clonal common targets, which overcome the intra- and inter-tumoral 525 
heterogeneity.  526 
An in-depth understanding of how tumors evade immune surveillance will help develop effective 527 
therapeutic strategies that can be used for the benefit of cancer patients. 528 
 529 
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Tables 1321 
Table 1. Cross-Validation of potential targets that may enhance anticancer immune responses to 1322 
other cancer hallmarks 1323 
POTENTIAL 
TARGETS for 
IMMUNE-
MODULATION 
 
 
Other Cancer 
Hallmarks  
(Promote/ 
Enhance) 
Th1 
responses 
via 
increase 
number of 
NK cells   
(Promote/ 
Enhance)  
γδ T cell 
activities 
(Promote/ 
Activate) 
macrophages 
(Inhibit) Treg 
lymphocytes  
(Promote/ 
Enhance)  
NK cell 
activity 
(Promote/ 
Induce)  
IL-12 
Genomic 
Instability 
0 0 0 0 0 0 
Sustained 
Proliferative 
Signaling 
0 0 - 
 [207] 
0 0 0 
Tumor- 
Promoting 
Inflammation 
- 
 [208,209] 
- 
 [210] 
+ 
 [211] 
+/- 
 [212-214] 
+ 
 [215,216] 
+ 
 [217,218] 
Evasion of  
Anti-growth 
Signaling 
0 + 
 [219] 
0 + 
 [220] 
+ 
 [221] 
0 
Resistance to 
Apoptosis 
0 0 + 
 [222] 
+ 
 [223] 
0 - 
 [224] 
Replicative 
Immortality 
+ 
 [225] 
0 0 0 + 
 [225] 
0 
Deregulated 
Metabolism 
0 0 0 0 0 0 
 Angiogenesis + 
 [226-229] 
- 
 [230-233] 
+/- 
 
[234] 
+ 
 [235] 
+ 
 [236] 
+ 
 [237] 
Tissue 
Invasion and 
Metastasis  
+ 
 [238] 
+ 
 [239] 
- 
 [240] 
+ 
 [241] 
+ 
 [242] 
+ 
 [243] 
Tumor 
Microenviron
ment 
+ 
 [244] 
+ 
 [245] 
+/- 
 [246-248] 
+ 
 [249] 
+ 
 [250] 
+ 
 [251] 
The symbols presented above represent as follows: +, complementary; -, contrary; +/-, 1324 
controversial; 0, no known relationship.  1325 
 1326 
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Table 2. Cross-Validation of phytochemicals that may enhance anticancer immune responses to 1327 
other cancer hallmarks  1328 
Approach  
 
 
 
 
 
Other Cancer 
Hallmarks 
Ganoderma 
lucidum 
(polysaccha
ride 
fraction) 
Trametes 
versicolor 
(protein-
bound 
polysaccha-
ride-k) 
Astragalus 
membranaceus 
(polysaccha-
ride fraction) 
Lentinus 
edodes 
(polysaccha-    
ride L-II, 
lentinan) 
Astaxan-
thin 
polyphenol-
resveratrol 
analogue 
HS-1793 
Genomic 
Instability 
0 0 0 0 0 0 
Sustained 
Proliferative 
Signaling 
+ 
 [,252] 
0 0 + 
 [253,254] 
+ 
 [255-257] 
0 
Tumor- 
Promoting 
Inflammation 
+ 
 [258,259] 
0 + 
 [260] 
+ 
 [261,262] 
+ 
 [263,264] 
0 
Evasion of 
Anti-growth 
Signaling 
+ 
 [265,266] 
+ 
 [267] 
+ 
 [268] 
+ 
 [269] 
+ 
 [270] 
0 
Resistance to 
Apoptosis 
+ 
 [271] 
0 + 
 [272] 
+ 
 [273] 
+ 
 [274] 
+ 
 [275] 
Replicative 
Immortality 
+ 
 [276] 
0 0 0 0 0 
Deregulated 
Metabolism 
0 0 0 0 0 0 
Angiogenesis + 
 [277,278] 
0 - 
 [279] 
+ 
 [280] 
0 + 
 [281] 
Tissue 
Invasion and 
Metastasis  
+ 
 [282] 
0 + 
 [283] 
+ 
 [284] 
+ 
 [285] 
+ 
 [286,287] 
Tumor 
Microenviron
ment 
+ 
 [288] 
+ 
 [289] 
+ 
 [290] 
+ 
 [291,292] 
+ 
 [293] 
+ 
 [294] 
The symbols presented above represent as follows: +, complementary; -, contrary; +/-, 1329 
controversial; 0, no known relationship.  1330 
1331 
Page 60 of 64
Ac
ce
pte
d M
an
us
cri
pt
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
61 
 
Figure legends 1332 
Figure 1. Tumor growth and immune response. An overview of the different key factors 1333 
governing tumor formation, progression, and immune evasion. The numbers in parentheses 1334 
represent the relevant references in support of the statements made. 1335 
 1336 
Figure 2. Tumor heterogeneity and immune response. Shown here are important sequential 1337 
events leading to tumor heterogeneity and its consequences for the various aspects of the 1338 
immune response. The numbers in parentheses are the relevant literature cited.  1339 
 1340 
Figure 3. Immune system and tumor metastasis. Depicted here are the key sequential events 1341 
based on the “Progression Model” leading to cancer cells exodus from the primary location and 1342 
subsequent establishment at a distant location and the possible role of various immune 1343 
modulators that aid this process. The numbers in parentheses are the relevant literature cited. 1344 
 1345 
Figure 4. Cancer therapy. A brief overview of the various available therapeutic options for 1346 
cancer. A few of these have entered clinical trials some of which have been approved for 1347 
treatment of specific types of cancers. The numbers in parentheses are the literature cited. 1348 
 1349 
 1350 
 1351 
Page 61 of 64
Ac
ce
pte
d M
an
us
cri
pt
Interaction 
between tumor 
formation and 
immune responses 
Tumor progression 
and immunity 
Immune evasion by 
cancer 
 Infection, stress, 
inflammation            
Tumor growth ,   
Survival ,  
Angiogenesis   
    [3, 6-9] 
 
 Autoimmune 
diseases          
Tumor growth  
[6,10-12] 
 Immunoediting            
Tumor  [13-15] 
 Tregs [17-22] 
MDSCs [23,24, 26] 
 Cytokines 
[22,28,30,39-44] 
M2 macrophages 
[28-30] 
 Defective Ag 
presentation [32-38] 
 Immune 
suppressive 
mediators (VEGF, 
RCAS1, tumor 
gangliosides, IDO, 
arginase, IKK2 [31, 
45,47-58]) 
 Tolerance and 
immune deviation 
[59,60] 
 Apoptosis [66,67] 
 
Tumor growth and immune responses 
Figure 1 
Figure
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Morphological and epigenetic plasticity 
Tumor heterogeneity 
 Tumors-specific 
transplantation Ags 
 Tumor-associated 
Ags 
 Differentiation Ags 
 Histocompatibility 
Ags 
    [68,69] 
 Genotype 
 Gene expression 
 Cellular morphology 
Metabolic activity 
Motility 
 Behavior 
(proliferation rate, Ag 
presentation, drug 
response, and 
metabolic potential 
    [70-74]) 
 
 
Figure 2 
Figure
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Figure 3 
Key factors governing the tumor metastasis 
Mutational events 
within the primary 
tumor (Progression 
Model)  Cancer cell 
exodus   Metastasis 
 [84-88] 
Immune mediators 
(TGF-β , VEGF , HIF 
, iNOS , hypoxia ) 
by cancer cells  
Metastasis  [89-93] 
Figure
Page 64 of 64
Ac
ce
pte
d M
an
us
cri
pt
Important avenues of cancer therapy 
 Chemotherapy 
 Radiation therapy 
 Immunotherapy 
 Targeted therapy 
 Surgery 
    [125] 
 Vaccination with 
peptides and DCs 
[186-190] 
 Alloreactive effector 
cells [129] 
 Cellular targets 
(Tregs [136-138], 
MDSCs [136-138], 
type II NK cells, 
macrophages 
[3,141,142], 
regulatory DCs [141]) 
Molecular targets 
(CTLA-4 [145,160-
164], 4-1BB [146], 
PD-1/PD-L1 
[147,165], AITR, 
TIM-3, LAG-3, OX40, 
CD40, CD39, CD73, 
A2A [148], MAGES 
[149], CTL Ags [149], 
BAGE and GAGE 
[149,151], LAGE 
[153], PRAME [153], 
hTERT [154], WT1 
[157], STAT3 
[168,169], bacteria 
[132], adenosine, 
CD73 [170,178]), pH 
regulation 
Figure 4 
Figure
